



Zosano Pharma  
Investor Relations Department  
34790 Ardentech Ct.  
Fremont, CA 94555  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: ZSAN

Last Trade:	16.89
Trade Time:	4:00 PM ET Mar 22, 2018
Change:	-0.38  (-2.200%)
Day Range	16.50 - 19.10
52-Week Range	3.61 - 41.60
Volume	610,834

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company's proprietary transdermal delivery system. The Company's goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Mar 16, 2018

[Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study](#)

Mar 12, 2018

[Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update](#)

Mar 2, 2018

[Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine](#)

Jan 25, 2018

[Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split](#)

Jan 3, 2018

[Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine](#)

## Financials [\[ View all \]](#)

Mar 12, 2018

[Annual Report \(10-K\)](#)

Dec 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 10, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)